NUMBER patients locoregional carcinoma prostate prostate specific antigen psa levels evaluated external beam radiotherapy median NUMBER months NUMBER patients NUMBER initial psa levels exceeded maximum normal value NUMBER patients kept high levels just radiotherapy free disease assuming psa levels decrease exponentially radiotherapy mean NUMBER days median NUMBER sd NUMBER days calculated patients psa NUMBER days relapsed compared NUMBER relapse rate patients normal prolonged psa suggests residual disease psa levels expected decrease radiation months irradiation persistent high psa levels NUMBER patients evidence manifest disease important negative prognostic factors disease control series high levels psa psa serum exceeding NUMBER days persistence elevated psa values longer months treatment opinion psa valuable marker prostate cancer patients radiotherapy follow non declining half life half life half life half life non declining half life follow ng ml NUMBER NUMBER NUMBER NUMBER